title: [Treatment of acute leukemia with "MB-triple V" therapy--a comparative study of "MB-triple V" therapy and B-triple V therapy].
abstract: Eleven patients with acute leukemia were treated with MB-triple V therapy consisting of mitoxantrone, behenoyl-arabinoside, etoposide, vincristine and vindesine. In this regimen, the target points were set for WBC count in the peripheral blood (less than 1,500/microliters) and TNC count in the bone marrow (less than 15,000/microliters). In this study, we compared the WBC count in nadir state and the duration until WBC count returned to above 1,000/microliters between 11 patients with MB-triple V therapy and 15 patients with B-triple V therapy in which target points were not set. In particular, the standard distribution of WBC count in nadir state of MB-triple V group was significantly smaller than that of B-triple V group. The number of early deaths in the course of MB-triple V (0/11, 0%) decreased compared with B-triple V group (3/15, 20%). Seven patients of the eleven patients with this regimen achieved CR state (63.6%). Hereafter, further cases are necessary before this combination chemotherapy as a part of the induction therapy is evaluated.
authors.affiliation: Osaka City University Medical School, Dept. of Laboratory Medicine.
authors.forename: T
authors.initials: T
authors.lastname: Yamane
authors.forename: T
authors.initials: T
authors.lastname: Inoue
authors.forename: Y
authors.initials: Y
authors.lastname: Furukawa
authors.forename: A
authors.initials: A
authors.lastname: Sasaki
authors.forename: T
authors.initials: T
authors.lastname: Kishida
authors.forename: K
authors.initials: K
authors.lastname: Park
authors.forename: T
authors.initials: T
authors.lastname: Im
authors.forename: N
authors.initials: N
authors.lastname: Tatsumi
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007938:Leukemia / Q000097:blood / Q000188:drug therapy*; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D012074:Remission Induction; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D014750:Vincristine; D014747:Vinblastine; D005047:Etoposide; D008942:Mitoxantrone; D014751:Vindesine